Metastatic Pancreatic Cancer Clinical Trials

39 recruitingLast updated: June 17, 2026

There are 39 actively recruiting metastatic pancreatic cancer clinical trials across 14 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1. Top locations include Shanghai, Shanghai Municipality, China, Tianjin, Tianjin Municipality, China, Nanjing, Jiangsu, China. Updated daily from ClinicalTrials.gov.


Metastatic Pancreatic Cancer Trials at a Glance

39 actively recruiting trials for metastatic pancreatic cancer are listed on ClinicalTrialsFinder across 6 cities in 14 countries. The largest study group is Phase 2 with 24 trials, with the heaviest enrollment activity in Shanghai, Tianjin, and Nanjing. Lead sponsors running metastatic pancreatic cancer studies include Alpha Tau Medical LTD., National Cancer Institute (NCI), and Tianjin Medical University Cancer Institute and Hospital.

Browse metastatic pancreatic cancer trials by phase

Treatments under study

About Metastatic Pancreatic Cancer Clinical Trials

Looking for clinical trials for Metastatic Pancreatic Cancer? There are currently 33 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Pancreatic Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Pancreatic Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 39 trials

Recruiting
Not Applicable

Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer (Feasibility and Safety)

Pancreatic CancerMetastatic Pancreatic CancerPancreatic Adenocarcinoma+1 more
Alpha Tau Medical LTD.15 enrolled2 locationsNCT05657743
Recruiting
Not Applicable

Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer

Pancreatic CancerMetastatic Pancreatic CancerPancreatic Adenocarcinoma
Alpha Tau Medical LTD.40 enrolled15 locationsNCT06698458
Recruiting
Phase 1

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Advanced Breast CancerAdvanced Solid TumorsMetastatic Pancreatic Cancer+3 more
National Cancer Institute (NCI)116 enrolled2 locationsNCT04222413
Recruiting
Phase 2

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Metastatic Breast CarcinomaMetastatic Ovarian CancerMetastatic Pancreatic Cancer+2 more
National Cancer Institute (NCI)332 enrolled1 locationNCT01174121
Recruiting
Phase 3

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Pancreatic CancerMetastatic Pancreatic CancerMetastatic Pancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc.614 enrolled17 locationsNCT07409272
Recruiting
Phase 1

A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors

Metastatic Breast CancerAdvanced Solid TumorMetastatic Ovarian Cancer+3 more
EtiraRx Australia Pty Ltd36 enrolled5 locationsNCT06533332
Recruiting
Phase 2Phase 3

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer
Hutchmed502 enrolled2 locationsNCT06361888
Recruiting
Phase 1Phase 2

NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer

Locally advanced and metastatic pancreatic cancerPancreatic Ductal Adenocarcinoma (PDAC)
West China Hospital55 enrolled1 locationNCT07595172
Recruiting
Early Phase 1

First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer

Metastatic Pancreatic CancerLocally Advanced Pancreatic Adenocarcinoma
University of California, Davis30 enrolled1 locationNCT04665947
Recruiting
Phase 1Phase 2

Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

Metastatic Pancreatic CancerPancreatic AdenocarcinomaBasal Cell Neoplasm
UNC Lineberger Comprehensive Cancer Center104 enrolled1 locationNCT06483555
Recruiting
Phase 2

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Endometrial CancerLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm+10 more
Rahul Aggarwal89 enrolled3 locationsNCT03682289
Recruiting
Phase 2

Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients

Metastatic Pancreatic Cancer
Institut du Cancer de Montpellier - Val d'Aurelle162 enrolled8 locationsNCT05065801
Recruiting
Not Applicable

Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients

Metastatic Pancreatic CancerAdvanced Pancreatic Cancer
Centre Leon Berard750 enrolled1 locationNCT05380414
Recruiting
Phase 1

A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors

Metastatic Breast CancerEndometrial CancerAdvanced Solid Tumor+6 more
Institut Paoli-Calmettes27 enrolled1 locationNCT05143970
Recruiting
Phase 1Phase 2

Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC

Metastatic Pancreatic CancerPancreas CancerPancreatic Adenocarcinoma+1 more
Mayo Clinic40 enrolled1 locationNCT04605913
Recruiting
Phase 2

Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients

Advanced Metastatic Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School56 enrolled1 locationNCT06662006
Recruiting
Phase 3

The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer

Metastatic Pancreatic CancerVenous ThromboembolismLocally Advanced Pancreatic Adenocarcinoma
Quercis Pharma AG480 enrolled3 locationsNCT06861088
Recruiting
Phase 1

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

Breast Cancer MetastaticHER2-Negative Breast CarcinomaPancreatic Cancer+17 more
General Oncology, Inc.24 enrolled2 locationsNCT04150042
Recruiting
Phase 2

QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital33 enrolled1 locationNCT06951997
Recruiting
Phase 1Phase 2

HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors

Locally Advanced or Metastatic Pancreatic Cancer With
Shanghai Hengrui Pharmaceutical Co., Ltd.60 enrolled1 locationNCT07296341